Bronchiectasis and chronic suppurative lung disease in Australia and New Zealand. Thoracic Society of Australia and New Zealand Position Statement.

Show simple item record Chang, AB Bell, SC Byrnes, CA Grimwood, K Holmes, P King, PT Kolbe, J Landau, LI Maguire, GP McDonald, M Reid, D Thien, F Antic, R Torzillo, PJ 2022-06-29T02:20:19Z 2022-06-29T02:20:19Z 2009
dc.identifier.citation (2009). Medical Journal of Australia, 193(6), 356-365.
dc.identifier.issn 0025-729X
dc.description.abstract • Consensus recommendations for managing chronic suppurative lung disease (CSLD) and bronchiectasis, based on systematic reviews, were developed for Australian and New Zealand children and adults during a multidisciplinary workshop. • The diagnosis of bronchiectasis requires a high-resolution computed tomography scan of the chest. People with symptoms of bronchiectasis, but non-diagnostic scans, have CSLD, which may progress to radiological bronchiectasis. • CSLD/bronchiectasis is suspected when chronic wet cough persists beyond 8 weeks. Initial assessment requires specialist expertise. Specialist referral is also required for children who have either two or more episodes of chronic (>4 weeks) wet cough per year that respond to antibiotics, or chest radiographic abnormalities persisting for at least 6 weeks after appropriate therapy. • Intensive treatment seeks to improve symptom control, reduce frequency of acute pulmonary exacerbations, preserve lung function, and maintain a good quality of life. • Antibiotic selection for acute infective episodes is based on results of lower airway culture, local antibiotic susceptibility patterns, clinical severity and patient tolerance. Patients whose condition does not respond promptly or adequately to oral antibiotics are hospitalised for more intensive treatments, including intravenous antibiotics. • Ongoing treatment requires regular and coordinated primary health care and specialist review, including monitoring for complications and comorbidities. • Chest physiotherapy and regular exercise should be encouraged, nutrition optimised, environmental pollutants (including tobacco smoke) avoided, and vaccines administered according to national immunisation schedules. • Individualised long-term use of oral or nebulised antibiotics, corticosteroids, bronchodilators and mucoactive agents may provide a benefit, but are not recommended routinely.
dc.relation.ispartofseries Medical Journal of Australia
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.
dc.subject 11 Medical and Health Sciences
dc.subject 17 Psychology and Cognitive Sciences
dc.title Bronchiectasis and chronic suppurative lung disease in Australia and New Zealand. Thoracic Society of Australia and New Zealand Position Statement.
dc.type Journal Article
dc.identifier.doi 10.5694/j.1326-5377.2010.tb03949.x
pubs.issue 6
pubs.begin-page 356
pubs.volume 193 2022-05-27T01:47:04Z
dc.rights.holder Copyright: The author en
dc.identifier.pmid 20854242 (pubmed)
pubs.end-page 365
pubs.publication-status Published
dc.rights.accessrights en
pubs.subtype Article
pubs.elements-id 165925 Medical and Health Sciences School of Medicine Medicine Department Paediatrics Child & Youth Hlth
dc.identifier.eissn 1326-5377
pubs.record-created-at-source-date 2022-05-27

Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace